Results 71 to 80 of about 1,494 (190)

Accelerating Pediatric Oncology Drug Development: Advances in Clinical Pharmacology, Trial Design, Non‐Clinical Evidence, and Regulatory Science

The Journal of Clinical Pharmacology, Volume 66, Issue 7, July 2026.
Abstract Pediatric oncology drug development remains uniquely challenging due to the rarity and biological heterogeneity of childhood cancers, ethical considerations in trial conduct, and the limited feasibility of large, randomized studies. Despite these barriers, recent years have seen a notable acceleration in the approval of oncology therapies for ...
Ya‐Feng Wen, Xiaoning Wang, Sarandeep Boyanapalli, Lee Anderson, Thao Dang, Guan Xing, Marianna Calvet, Tiffany Hart, Sreeneeranj Kasichayanula, Xiaochen Zhao   +9 more
wiley   +1 more source

Blastic plasmacytoid dendritic cell neoplasm and cerebral toxoplasmosis: a case report

BMC Neurology, 2022
Background The present case contributes to the limited literature on central nervous system involvement of blastic plasmacytoid dendritic cell neoplasm (BPDCN).
Anna Maria Florescu, Anne Louise Tølbøll Sørensen, Henrik Vedel Nielsen, Daniel Tolnai, Lene Dissing Sjö, Katja Lohmann Larsen, Mohammad Al-Mahdi Al-Karagholi   +6 more
doaj   +1 more source

Whole-genome analysis uncovers recurrent IKZF1 inactivation and aberrant cell adhesion in blastic plasmacytoid dendritic cell neoplasm [PDF]

, 2020
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and highly aggressive hematological malignancy with a poorly understood pathobiology and no effective therapeutic options.
Mei H., Cats D., Bastidas Torres A. N., Tensen C. P., Gliozzo J., Willemze R., Paulli M., Corti L., Berti E., Vermeer M. H., Fanoni D., Davy Cats, Corti, Laura, Torres, A.N.B., Cats, Davy, Gliozzo, J., Paulli, M., Fanoni, Daniele, Emilio Berti, Jessica Gliozzo, Maarten H. Vermeer, Tensen, C.P., Berti, Emilio, Corti, L., Daniele Fanoni, Fanoni, D., Cats, D., Tensen, Cornelis P, Cornelis P. Tensen, Paulli, Marco, Marco Paulli, Bastidas Torres, Armando N, Armando N. Bastidas Torres, Mei, Hailiang, Laura Corti, Vermeer, M.H., Willemze, R., Gliozzo, Jessica, Berti, E., Rein Willemze, Vermeer, Maarten H, Mei, H.L., Hailiang Mei, Willemze, Rein   +43 more
core   +3 more sources

Pathology Quiz Case: Plasmacytoid Dendritic Cell Neoplasm

Allergy & Rhinology, 2014
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy that possesses a heterogenous clinical and immunophenotypic presentation. The current case report describes an interesting and unique presentation of BPDCN as a primary
Quinn A. Dunlap B.S., Kristine E. Day M.D., Samuel G. Borak M.D., Bradford A. Woodworth M.D.   +3 more
doaj   +1 more source

Liposomal Daunorubicin and Cytarabine, a Potential Therapy for Blastic Plasmacytoid Dendritic Cell Neoplasm

Journal of Investigative Medicine High Impact Case Reports, 2022
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare aggressive malignancy with poor outcomes. Although novel options like tagraxofusp, a CD123-directed cytotoxin, has emerged and is promising, treatment options are very limited in the relapsed
Prashanth Ashok Kumar MBBS, Mulham Ombada MBBS, Gayatri Pemmasani MBBS, Ajay Tambe MBBS, Katalin Banki MD, Teresa Gentile MD, PhD   +5 more
doaj   +1 more source

Two Blastic Plasmacytoid Dendritic Cell Neoplasms treated with the CD123‐targeted agent Tagraxofusp presenting divergent outcomes

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Sven C. Engler, Elisabeth M. Walde, Edgar Jost, Amir S. Yazdi, David Kluwig   +4 more
wiley   +1 more source

PRMT5 Inhibition Affects RNA Methylation and Is a Potential Therapeutic Target in BPDCN

Blood, 2020
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and clinically aggressive hematologic cancer that arises from malignant transformation of plasmacytoid dendritic cells (pDCs) and is predisposed to leukemic transformation. Apart from the recently approved therapy, Tagraxofusp-erzs, treatment options for BPDCN remain limited.
Malini Rethnam, Darren Qiancheng Tan, Shi Hao Tan, Li Ying, Henry Yang, Toshio Suda   +5 more
openaire   +1 more source

Frequent NPM1 mutation, monoblastic/monocytic origin and prognostic significance of organ and system involvement in myeloid sarcoma: a multicenter study

The Journal of Pathology: Clinical Research, Volume 12, Issue 2, March 2026.
Abstract Myeloid sarcoma (MS) is a tumorous extramedullary proliferation of blast or blast equivalent cells (e.g., promonocytes or promyelocytes). The most frequent cutaneous presentation is often referred to as leukemia cutis (LC). These lesions, especially without the clinical context of a known bone marrow disease, pose a differential diagnostic ...
Alex Jenei, Béla Kajtár, Tamás László, Hazem A Juratli, Livia Vida, Ágota Szepesi, Réka Mózes, Botond Timár, Jörg Halter, Stefan Dirnhofer, Alexandar Tzankov   +10 more
wiley   +1 more source

Structural design and property regulation of organic polymers for photocatalytic synthesis of H2O2

InfoScience, Volume 3, Issue 1, March 2026.
Photocatalytic synthesis of H2O2 offers a sustainable approach. Photocatalytic efficiency depends critically on interfacial electron transfer kinetics and spatial charge separation. Herein, we systematically analyze key factors governing photogenerated carrier dynamics and propose engineered strategies to optimize performance, thereby providing design ...
Mingyang Xu, Rongchen Shen, Yingyin Mo, Guijie Liang, Shijie Li, Peng Zhang, Xiaobo Chen, Youji Li, Xin Li   +8 more
wiley   +1 more source

Evaluation of diagnostic efficacy of NRP‐1/CD304 in hematological diseases

Cancer Medicine, 2023
Background Previous studies had explored the diagnostic or prognostic value of NRP‐1/CD304 in blastic plasmacytoid dendritic cell neoplasm (BPDCN), acute myeloid leukemia (AML), and B‐cell acute lymphoblastic leukemia (B‐ALL), whereas the expression and ...
Yi‐jun Liu, Xiao‐hui Li, Yi‐ling Song, Yi‐chen Zhou, Rong‐zeng Cai, Pei‐dong Chi   +5 more
doaj   +1 more source